About

Eva Anette Engelhardt is Executive Vice President and President, Clinical Diagnostics Group of Bio-Rad Laboratories, a role to which she was appointed in June 2024.

Prior to joining Bio-Rad, Ms. Engelhardt was at Cepheid, a wholly owned subsidiary of Danaher Corporation and a global molecular diagnostics company, where she served as Senior Vice President, Global R&D from November 2022 to May 2024 and as Senior Vice President and General Manager, Emerging & Growth Opportunities Business from March 2022 to November 2022. Before that she held several senior positions at bioMerieux Inc., a global in vitro diagnostics company, from 2010 to 2022, including Senior Vice President, New Technologies Franchise from 2019 to 2022 and Senior Vice President, Microbiology Business Area from 2014 to 2019. She also was CEO of privately held AB BIODISK from 2007 to 2010.

Ms. Engelhardt holds a combined Master of Science and Bachelor of Science degree in Chemical Engineering and Polymer Technology from the Royal Institute of Technology in Stockholm, Sweden.

Roles

Bio-Rad Laboratories, Inc.
Executive Vice President and President, Clinical Diagnostics Group · Current role
2024–present
Cepheid (a subsidiary of Danaher Corporation)
Senior Vice President, Global R&D · Served from November 2022 to May 2024.
2022–2024
Cepheid (a subsidiary of Danaher Corporation)
Senior Vice President and General Manager, Emerging & Growth Opportunities Business · Served from March 2022 to November 2022.
2022
bioMerieux Inc.
Senior Vice President, New Technologies Franchise
2019–2022
bioMerieux Inc.
Senior Vice President, Microbiology Business Area
2014–2019
AB BIODISK
Chief Executive Officer · AB BIODISK was a privately held company.
2007–2010
Cepheid (Danaher)
SVP Global R&D
2022-2024
bioMerieux
SVP New Technologies Franchise; SVP Microbiology Business Area
2010-2022

Also at Bio-Rad Laboratories, Inc.

Related

See how VectorShift works for your firm

Request Demo